TIVC

Tivic Health Systems Inc. (TIVC) | Rumor.io

Tivic Health Systems

TIVC

Attention (50-day avg)0%

Attention rank (50-day avg)#4,006

Bullish sentiment (50-day avg)8%

Price to earnings ratio0.04

Market capitalization8.7M

Earnings per share-6.92

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.9M

Social

What share of all stock conversation is about TIVC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 5

$TIVC may exceed its outstanding share issuance after its S1 filing in April, with a potential revision to 3.9 shares in the next update.
The company has a presentation scheduled on May 7th with the Department of War, which may be a key catalyst for the stock.
Institutional stakes in $TIVC are expected to increase with added liquidity, potentially leading to a base build and further price appreciation.

Generated by AI

Sentiment

Of the messages about TIVC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	85.53% -4.43
Bearish	—	—	0% -100	14.47% +4.43

Bullish· Apr 28

$TIVC has a large float of 2.86 million shares and a cash position of $3.5 per share, indicating a strong financial foundation.
A potential big pharma buyout could be in the works, with numbers starting in the triple digits, suggesting a significant revenue opportunity.
$TIVC is oversold and due for a move, with a low float and recent ticker change, similar to past instances of stocks like $NEXR and $SEGG.

Bearish· Apr 28

The company's CEO, Jennifer Ernst, has a questionable reputation, with some investors viewing her as a "scum CEO" who may have engaged in unethical practices.
The company is at risk of delisting due to non-compliance issues, which could have severe consequences for its shareholders.
The company's stock price is likely to drop further, with some investors predicting it will fall below $1 again, and others viewing it as a "garbage stock" with limited potential for growth.

Generated by AI

Topics

Of the messages about TIVC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	80.25%
Analysts	—	0%	0%	1.23%
Controversies	—	0%	0%	0.93%
Earnings	—	0%	0%	3.09%
Macro	—	0%	0%	0.31%
Technical Analysis	—	0%	0%	14.2%

Announcements· Aug 20

Tivic Health Systems, Inc. ($TIVC) received two Investigational New Drug Applications (IND) for Entolimod™ to treat Acute Radiation Syndrome (ARS) and Advanced Cancers.
The IND applications were received from Statera Biopharma, with Entolimod™ targeting ARS for potential military defense use and Advanced Cancers.
Tivic Health Systems has secured funding with a $25M equity line and $8.4M preferred deal, regaining Nasdaq compliance via a reverse stock split.

Technical Analysis· Dec 23

$TIVC is in a potentially bullish position, with a bounce in sight and a strong candle structure.
The stock has broken out and is showing high volume and RSI, with a target of the 200-day SMA on the daily chart.
Key levels to watch include support at $1.9, resistance at $2.66, and potential round-number levels at $3.23, $3.88, and $4.55.

Generated by AI

Community

Of the messages about TIVC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	80%	71.43%	37.54%
Newcomers	—	20%	28.57%	62.46%

Regulars· Dec 23

$TIVC is up 88% in a significant swing, with volume surging and RSI hitting high levels.
The stock broke out with strong momentum, prompting speculation about its next chart-topping performance.
$TIVC needs to break through a descending wedge and hold above its volume-weighted average price (VWAP) for a sustained recovery.

Newcomers· Dec 23

The company's acquisition of Scorpius' cGMP manufacturing assets and the formation of its CDMO subsidiary Velocity Bioworks have been significant transactions, potentially driving the stock's price.
Recent catalysts for the stock include progress toward cGMP manufacturing, strategic asset expansion, and a clearer path for Entolimod commercialization, which could lead to a re-rating on news flow.
Positive clinical data from the company's collaboration with the Feinstein Institute demonstrates the significant effectiveness of its personalized neurostimulation technology, validating its potential as a drug alternative and supporting a target price of $3.1-$3.9.

Generated by AI

Also Discussed

Investors talking about TIVC also mention

#	Name	Attention
1	MRAI - Marpai, Inc.	——
2	SMART Trend 25 ETFSTRN	0%0
3	AHI - Advanced Health Intelligence Ltd	——
4	Petvivo Holdings IncPETV	0%-0.01
5	CYNGN Inc.CYN	0%0
6	Kidpik Corp.PIK	0%new
7	Context Therapeutics Inc.CNTX	0%0
8	Bluejay Diagnostics Inc.BJDX	0%0
9	RVLP - RVL Pharmaceuticals plc	——
10	ZVSA - ZyVersa Therapeutics, Inc.	——

Tivic Health Systems Inc.

Healthcare
Medical Devices

Tivic Health Systems Inc. is a health tech company specializing in bioelectronic medicine and immunotherapeutics. It develops and commercializes innovative treatments focused on restoring healthy immune system function through TLR5 biologics programs and non-invasive cervical vagus nerve stimulation devices. The company's lead drug candidate, Entolimod, targets Acute Radiation Syndrome by activating innate immune pathways to prevent cell death in bone marrow and epithelial tissues. Its pipeline also includes applications for Neutropenia, lymphocyte exhaustion, and Entolasta, an optimized variant for chronic conditions. Previously known for the ClearUP device treating sinus and nasal inflammation, Tivic sells products via direct-to-consumer channels including its websites, Amazon.com, Walmart.com, BestBuy, and FSAStore, as well as through distributors. Additionally, it operates Velocity Bioworks, a subsidiary providing contract development and manufacturing services to biotech firms while supporting its own pipeline for enhanced supply chain control. Incorporated in 2016 and headquartered in Fremont, California, Tivic Health Systems Inc. plays a role in advancing immunomodulation therapies and biomanufacturing in the healthcare sector.

Website

Location

47685 Lakeview Blvd.

Fremont, CA, 94538

United States

Social

What share of all stock conversation is about TIVC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 5

$TIVC may exceed its outstanding share issuance after its S1 filing in April, with a potential revision to 3.9 shares in the next update.
The company has a presentation scheduled on May 7th with the Department of War, which may be a key catalyst for the stock.
Institutional stakes in $TIVC are expected to increase with added liquidity, potentially leading to a base build and further price appreciation.

Generated by AI

Sentiment

Of the messages about TIVC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	85.53% -4.43
Bearish	—	—	0% -100	14.47% +4.43

Bullish· Apr 28

$TIVC has a large float of 2.86 million shares and a cash position of $3.5 per share, indicating a strong financial foundation.
A potential big pharma buyout could be in the works, with numbers starting in the triple digits, suggesting a significant revenue opportunity.
$TIVC is oversold and due for a move, with a low float and recent ticker change, similar to past instances of stocks like $NEXR and $SEGG.

Bearish· Apr 28

The company's CEO, Jennifer Ernst, has a questionable reputation, with some investors viewing her as a "scum CEO" who may have engaged in unethical practices.
The company is at risk of delisting due to non-compliance issues, which could have severe consequences for its shareholders.
The company's stock price is likely to drop further, with some investors predicting it will fall below $1 again, and others viewing it as a "garbage stock" with limited potential for growth.

Generated by AI

Topics

Of the messages about TIVC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	80.25%
Analysts	—	0%	0%	1.23%
Controversies	—	0%	0%	0.93%
Earnings	—	0%	0%	3.09%
Macro	—	0%	0%	0.31%
Technical Analysis	—	0%	0%	14.2%

Announcements· Aug 20

Tivic Health Systems, Inc. ($TIVC) received two Investigational New Drug Applications (IND) for Entolimod™ to treat Acute Radiation Syndrome (ARS) and Advanced Cancers.
The IND applications were received from Statera Biopharma, with Entolimod™ targeting ARS for potential military defense use and Advanced Cancers.
Tivic Health Systems has secured funding with a $25M equity line and $8.4M preferred deal, regaining Nasdaq compliance via a reverse stock split.

Technical Analysis· Dec 23

$TIVC is in a potentially bullish position, with a bounce in sight and a strong candle structure.
The stock has broken out and is showing high volume and RSI, with a target of the 200-day SMA on the daily chart.
Key levels to watch include support at $1.9, resistance at $2.66, and potential round-number levels at $3.23, $3.88, and $4.55.

Generated by AI

Community

Of the messages about TIVC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	80%	71.43%	37.54%
Newcomers	—	20%	28.57%	62.46%

Regulars· Dec 23

$TIVC is up 88% in a significant swing, with volume surging and RSI hitting high levels.
The stock broke out with strong momentum, prompting speculation about its next chart-topping performance.
$TIVC needs to break through a descending wedge and hold above its volume-weighted average price (VWAP) for a sustained recovery.

Newcomers· Dec 23

The company's acquisition of Scorpius' cGMP manufacturing assets and the formation of its CDMO subsidiary Velocity Bioworks have been significant transactions, potentially driving the stock's price.
Recent catalysts for the stock include progress toward cGMP manufacturing, strategic asset expansion, and a clearer path for Entolimod commercialization, which could lead to a re-rating on news flow.
Positive clinical data from the company's collaboration with the Feinstein Institute demonstrates the significant effectiveness of its personalized neurostimulation technology, validating its potential as a drug alternative and supporting a target price of $3.1-$3.9.

Generated by AI

Tivic Health Systems

Social

May 5

Sentiment

Bullish· Apr 28

Bearish· Apr 28

Topics

Announcements· Aug 20

Technical Analysis· Dec 23

Community

Regulars· Dec 23

Newcomers· Dec 23

Also Discussed

Tivic Health Systems Inc.

Company Information

Location

Also Discussed

Social

May 5

Sentiment

Bullish· Apr 28

Bearish· Apr 28

Topics

Announcements· Aug 20

Technical Analysis· Dec 23

Community

Regulars· Dec 23

Newcomers· Dec 23